Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
ABL1 25 CHEMBL200177 CHEMBL200177 DrugBank 10592235
ABL1 25 BLINATUMOMAB CHEMBL1742992 FDA
ABL1 25 OXALIPLATIN CHEMBL414804 NCI 10098743
ABL1 25 MASITINIB CHEMBL1908391 TdgClinicalTrial
ABL1 25 BAFETINIB CHEMBL206834 inhibitor MyCancerGenome, GuideToPharmacologyInteractions, ChemblInteractions
ABL1 25 CELECOXIB CHEMBL118 NCI 16917206
ABL1 25 VENETOCLAX CHEMBL3137309 CGI
ABL1 25 TRAMETINIB CHEMBL2103875 CGI
ABL1 25 SARACATINIB CHEMBL217092 inhibitor GuideToPharmacologyInteractions, ChemblInteractions
ABL1 25 AZM-475271 CHEMBL3545150 inhibitor ChemblInteractions
ABL1 25 DASATINIB CHEMBL1421 inhibitor, multitarget OncoKB, PharmGKB, CGI, FDA, DrugBank, MyCancerGenome, TdgClinicalTrial, TEND, CIViC, CKB, DoCM, GuideToPharmacologyInteractions, ChemblInteractions 17496201, 11287973, 20131302, 12200353, 17701954, 11752352, 17016423, 20537386, 18818391, 26758680, 21562040, 12399961, 21505103, 11964322, 11853795, 14559829, 18615627, 25157968, 14745431, 19652056, 20697894, 24456693, 15256422, 19466505, 23676790, 15381060, 20367437, 21895409
ABL1 25 XL-228 CHEMBL3545085 inhibitor MyCancerGenome, TdgClinicalTrial, ChemblInteractions, DrugBank
ABL1 25 BOSUTINIB CHEMBL288441 inhibitor MyCancerGenome, TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, CGI, DrugBank, DoCM, FDA 21562040, 12399961, 21505103, 11964322, 11853795, 14559829, 18615627, 25157968, 14745431, 19652056, 20697894, 24456693, 15256422, 19466505, 23676790, 15381060, 20367437, 21895409, 12623848, 21489624, 21605905, 17114651, 18828913
ABL1 25 REGORAFENIB CHEMBL1946170 inhibitor ChemblInteractions, DrugBank
ABL1 25 IMATINIB CHEMBL941 inhibitor CGI, GuideToPharmacologyInteractions, FDA, OncoKB, TEND, TdgClinicalTrial, MyCancerGenome, CIViC, CKB 11287973, 12637609, 20525993, 20525995, 22160483, 11287972, 23502220, 17496201, 20131302, 12200353, 12476305, 20537386, 15194504, 19075254, 15930265, 26758680
ABL1 25 AT-9283 CHEMBL495727 inhibitor MyCancerGenome, ChemblInteractions
ABL1 25 Pexmetinib CHEMBL3545297 TdgClinicalTrial
ABL1 25 ACYCLOVIR CHEMBL184 NCI 8683981
ABL1 25 AXITINIB CHEMBL1289926 CGI
ABL1 25 FORETINIB CHEMBL1230609 CGI
ABL1 25 VANDETANIB CHEMBL24828 CGI
ABL1 25 PILOCARPINE CHEMBL550 inhibitor GuideToPharmacologyInteractions
ABL1 25 PONATINIB HYDROCHLORIDE CHEMBL2105708 inhibitor ChemblInteractions
ABL1 25 AZD-0424 CHEMBL3545177 inhibitor ChemblInteractions
ABL1 25 NILOTINIB CHEMBL255863 inhibitor DrugBank, OncoKB, TdgClinicalTrial, MyCancerGenome, CGI, CKB, FDA, TEND, CIViC, DoCM, GuideToPharmacologyInteractions 19822896, 19920925, 17715389, 16721371, 17929114, 11287973, 12637609, 20525993, 20525995, 22160483, 11287972, 23502220, 28514312, 20537386, 19075254, 21562040, 11964322, 12623848, 21489624, 23676790, 20367437, 25157968, 21605905, 21895409, 17114651, 18828913
ABL1 25 HYDROXYUREA CHEMBL467 NCI 7923130
ABL1 25 IMATINIB MESYLATE CHEMBL1642 inhibitor ChemblInteractions, NCI 12910520, 16205964
ABL1 25 QUERCETIN CHEMBL50 NCI 9349317
ABL1 25 ENMD-2076 CHEMBL482968 TdgClinicalTrial
ABL1 25 CABOZANTINIB CHEMBL2105717 CGI
ABL1 25 CHEMBL1081312 CHEMBL1081312 inhibitor GuideToPharmacologyInteractions
ABL1 25 REBASTINIB CHEMBL1738757 inhibitor GuideToPharmacologyInteractions, ChemblInteractions
ABL1 25 NILOTINIB HYDROCHLORIDE MONOHYDRATE CHEMBL1201740 inhibitor ChemblInteractions
ABL1 25 BUSULFAN CHEMBL820 FDA
ABL1 25 ADENOSINE TRIPHOSPHATE CHEMBL14249 inhibitor DrugBank 11752352, 17139284, 17016423
ABL1 25 MYRISTIC ACID CHEMBL111077 DrugBank 10592235
ABL1 25 CHEMBL327127 CHEMBL327127 DrugBank 10592235
ABL1 25 PONATINIB CHEMBL1171837 inhibitor MyCancerGenome, TdgClinicalTrial, GuideToPharmacologyInteractions, CGI, CIViC, DrugBank, DoCM, FDA 21562040, 12399961, 21505103, 11964322, 11853795, 14559829, 18615627, 25157968, 14745431, 19652056, 20697894, 24456693, 15256422, 19466505, 23676790, 15381060, 20367437, 21895409, 20512393, 11861307, 11423618, 23355941, 24236021, 22772060, 15194504, 22870928, 12130516, 21872826, 20537386, 23540562, 12623848, 20963643, 21762985, 22306673, 21489624, 21605905, 17114651, 18828913, 23409026, 23190221, 25349473
ABL1 25 GENISTEIN CHEMBL44 NCI 9349317
ABL1 25 MELPHALAN CHEMBL852 NCI 7923130
ABL1 25 CRIZOTINIB CHEMBL601719 CGI
ABL1 25 KW-2449 CHEMBL1908397 inhibitor GuideToPharmacologyInteractions, ChemblInteractions
ABL1 25 ABL-001 CHEMBL3545115 inhibitor ChemblInteractions
ABL1 25 Flumatinib CHEMBL3545413 inhibitor ChemblInteractions
ABL1 25 PROGESTERONE CHEMBL103 NCI 10195429
ABL1 25 AZACITIDINE CHEMBL1489 NCI 2425967

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
ABL1 rs121913459 T nilotinib efficacy no Allele T is associated with resistance to nilotinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele C. 25950190 1447814549
ABL1 rs121913459 T homoharringtonine efficacy no Patient received received omacetaxine, treatment had been stopped after two cycles because of clinical intolerance, but a major molecular response and total disappearance of the T315I clone was obtained. Treatment with dasatinib was then started and after 34-month follow-up the patient is still in major molecular response. Allele T is associated with response to homoharringtonine in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele C. 25950190 1447814556